Cargando…
Hypericin, a potential new BH3 mimetic
Many types of cancer such as prostate cancer, myeloid leukemia, breast cancer, glioblastoma display strong chemo resistance, which is supported by enhanced expression of multiple anti-apoptotic Bcl-2, Bcl-XL and Mcl-1 proteins. The viable anti-cancer strategies are based on developing anti-apoptotic...
Autores principales: | Doroshenko, Anastasia, Tomkova, Silvia, Kozar, Tibor, Stroffekova, Katarina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577225/ https://www.ncbi.nlm.nih.gov/pubmed/36267274 http://dx.doi.org/10.3389/fphar.2022.991554 |
Ejemplares similares
-
Hypericin in the Dark: Foe or Ally in Photodynamic Therapy?
por: Huntosova, Veronika, et al.
Publicado: (2016) -
BH3 Mimetics for the Treatment of Prostate Cancer
por: Wolf, Philipp
Publicado: (2017) -
Effect of the BH3 Mimetic Polyphenol (–)-Gossypol (AT-101) on the in vitro and in vivo Growth of Malignant Mesothelioma
por: Benvenuto, Monica, et al.
Publicado: (2018) -
Hypericins as Potential Leads for New Therapeutics
por: Karioti, Anastasia, et al.
Publicado: (2010) -
Mitochondrial apoptosis and BH3 mimetics
por: Dai, Haiming, et al.
Publicado: (2016)